Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sangamo Therapeutics, Inc. - Common Stock (NQ:SGMO)

0.4792 +0.0292 (+6.49%)
Streaming Delayed Price Updated: 11:45 AM EST, Dec 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sangamo Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
This CarMax Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗
 
Via Benzinga
News headline image
Sangamo (SGMO) Q3 2025 Earnings Call Transcript ↗
Sangamo (SGMO) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Sangamo Therapeutics Inc (NASDAQ:SGMO) Stock Plummets 22% After Q3 Earnings Miss ↗
Sangamo stock plunges 22% after Q3 earnings miss, with revenue of $0.58M falling far short of the $35.09M analyst estimate. 
Via Chartmill
Topics Earnings
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 12, 2025 ↗
 
Via Benzinga
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Discover the top movers in Thursday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
Sangamo Therapeutics Inc (NASDAQ:SGMO) Reports Q2 2025 Earnings: Revenue Misses but Narrower-Than-Expected Loss ↗
Sangamo Therapeutics (SGMO) reported Q2 2025 results with revenue missing estimates at $18.31M but a narrower loss of $0.08/share. Shares fell 9% post-earnings despite positive Fabry disease trial... 
Via Chartmill
News headline image
Tuesday's pre-market session: top gainers and losers ↗
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
These stocks are moving in today's session ↗
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Tuesday's session: top gainers and losers ↗
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
News headline image
Which stocks are moving before the opening bell on Tuesday? ↗
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
US Stocks Likely To Open Lower After A Strong Rally: 'Lows Are Likely In And Better Times Are Coming,' Says Expert ↗
U.S. stock futures fell on Tuesday after a stellar rally on Monday. Futures of major benchmark indices were trading lower in premarket. 
Via Benzinga
News headline image
Why Coinbase Global Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Which stocks are moving after the closing bell on Monday? ↗
The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
News headline image
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Sangamo Therapeutics Announces First Quarter 2025 Earnings Call
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Friday's pre-market session: top gainers and losers ↗
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
US Stocks Likely To Open Lower After The Worst Selloff Since 2020: Tariff Announcement Was '100% Smoot Hawley Disguised As Thoughtful Policy,' Says Expert ↗
U.S. stock futures continued to decline on Friday after a bloodbath on Thursday following the introduction of Donald Trump's tariffs. 
Via Benzinga
Topics Government
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.